IPO ROADSHOW PRESENTATION

A global leader in regenerative medicine for orthopedics, wound care, dermatology, and women’s health



AUTOLOGOUS PRP + HA

INTEGRATED PLATFORM

R&D • Clinical • Regulatory
Manufacturing • Direct Sales • Distributors

SEPTEMBER 2026 PROPOSED NASDAQ: RGNA REGENLAB USA, INC.

Forward-looking statements

This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by words or phrases such as “may,” “will,” “could,” “would,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “project,” “target,” “continue,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. In evaluating these forward-looking statements, you should consider various factors, including: our ability to develop and sell our proposed products; our ability to source, retain, and expand our technical and business staff to meet the demands of our expanding and diversifying business; our ability to raise the substantial amount of additional funds that will be necessary for our business to succeed, which funds may not be available on acceptable terms or available at all; assumptions relating to the size of the market for our products; unanticipated regulations of our products that add barriers to our business and have a negative effect on our operations; our estimates of expenses, future revenue, capital requirements and our needs for, or ability to obtain, additional financing; our status of an early-stage pre-net income company with a business model and marketing strategy still being developed and largely untested; our ability to avoid a significant disruption in our information technology system, including security breaches, or our ability to implement new system and software successfully; our ability to obtain and maintain intellectual property protection for our products; and other risks identified in our S-1 registration statement. The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with. Forward-looking statements necessarily involve risks and uncertainties, and our actual results could differ materially from those anticipated in the forward-looking statements due to a number of factors, including those set forth above. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise.

The offering

Issuer	RegenLab USA, Inc.
Transaction Type	Initial Public Offering
Proposed Symbol / Exchange	RGNA / NASDAQ
Shares Offered	[●] shares
Offering Price Per Share	$[●] - $[●]
Offering Size at Midpoint	$[●]
Use of Proceeds	[●]
Sole Book Running Manager	StoneX Financial Inc.

REGENLAB USA

First outside money since the company was founded 25 years ago

INVESTMENT THESIS

Established commercial scale + multiple near-term catalysts

01 ESTABLISHED COMMERCIAL BUSINESS

- 2025 net product sales: $49.2M
- 1H26 net product sales: $29.7M (+27%)
- 1H26 operating income: $2.5M

02 PROPRIETARY MODULAR PLATFORM

- Liquid PRP | PRP + HA | gel / fibrin | BMC
- Four therapeutic markets with common technology

03 CLINICAL + REGULATORY VALIDATION

- ~300 completed clinical studies
- 70 granted patents; U.S. 510(k) and PMA pathways

04 GLOBAL COMMERCIAL INFRASTRUCTURE

- 90+ countries served through direct sales + distributors
- Stryker, MiMedx, OPKO Health and Smith+Nephew relationships

05 CATALYST-RICH GROWTH PLAN

- U.S. wound care scale-up
- CellularMatrix U.S. PMA + RegenMatrix launch

25+	years operating history	90+	countries served	2M+	patients treated	3	manufacturing sites

Sources: Company materials; draft Form S-1, Amendment No. 3 (June 16, 2026).

ABOUT US

Vertically integrated regenerative medicine platform

RegenLab develops and commercializes standardized autologous PRP, PRP + HA and tissue-engineering technologies through an integrated operating platform

END-TO-END CAPABILITIES

R&D	Manufacturing	Clinical	Regulatory	IP	Commercial

FOUR THERAPEUTIC PLATFORMS

01

Musculoskeletal

Knee OA & orthobiologics

02

Advanced Wound Care

Chronic & surgical wounds

03

Medical Aesthetics

Dermatology & skincare

04

Women's Health

Urogynecology



Integrated operations across New Jersey, France & Switzerland

Three manufacturing sites • dedicated clinical/regulatory teams • global IP management

Source: RegenLab USA, Inc. Form S-1, Amendment No. 3 (June 16, 2026).

COMMERCIAL PRODUCTS

Revenue from direct sales & distribution agreements

Four principal product families for our autologous biologics and tissue engineering kits

PRP Preparation Kits
RegenKit® Family

Single-use, sterile tubes and accessories used to prepare platelet-rich plasma (PRP) at the point of patient care

CellularMatrix® Tubes
RegenPRP + Hyaluronic Acid

Sterile tubes combining PRP with hyaluronic acid (HA) for musculoskeletal, aesthetic and women's health procedures

Advanced Wound Care Kits
RegenKit® Wound Gel

Kits intended for the preparation of biologic bandages or dressings and application onto wounds


Bone Marrow Stem Cells
RegenExtracell Kits

Kits that combine trocar for marrow aspirate and PRP process combination for orthopedic surgery

REVENUE SOURCES

Diversified revenue mix

By Market



- Musculoskeletal (MSK) **65.0%**
- Medical Aesthetics **25.0%**
- Women's Health **2.5%**
- Advanced Wound Care **7.5%**

By Geography




- Europe **40.0%**
- Asia **30.0%**
- US **30.0%**

*Data as of 12/31/2025

OUR MARKETS

Four multibillion-dollar markets



Musculoskeletal

including knee osteoarthritis & tendinopathies

$6.2B

for sports medicine market in 2021[3]

- 750,000 knee joint procedures annually in the U.S.[4]

RegenKit | CellularMatrix



Advanced Wound Care

including diabetic foot ulcers

$8.0B

in 2022[5]

- 14-24% of the diabetic U.S. population with foot ulcers undergo foot amputation[6]
- 422M diabetic patients worldwide in 2014 (WHO)
- Worldwide average DFU prevalence is 6.3%[7]

RegenKit Wound Gel



Skincare

including skin aging, alopecia & urogenital


$4.1B

for HA **dermal filler** worldwide market in 2022[1]

$7.6B

for **alopecia** worldwide market in 2020[2]

RegenKit | CellularMatrix



Women's Health

including GSM & genital discomfort

$3.27B

Genitourinary syndrome of menopause

$3.57B


genital discomfort

RegenKit | CellularMatrix

First-in-class for knee osteoarthritis

Ranked #1 at 12 months in several meta-analyses 5,089 patients · 37 RCTs · corticosteroids ranked last

SUCRA RANKINGS AT 12 MONTHS (higher = better)



HEAD-TO-HEAD French RCT
Out of 28 RegenLab clinical studies

CellularMatrix vs. Synvisc-One (n=156)

Pain on walking (WOMAC A1)

Superior (p<0.05)

Lower AE rate than HA
No SAEs reported

Head-to-head: Delgado et al. 2022 (n=156).

Ref: Gupta et al. 2025 Bayesian network meta-analysis (37 RCTs 5,089 patients)

COMMERCIAL PARTNERSHIP

Stryker | established channel with 2027 expansion opportunity

Long-standing orthopedics & sports medicine relationship | RegenKit-THT → ExtraCell-BMC → potential broader collaboration

SINCE 2011 — 1

ESTABLISHED CHANNEL

RegenKit®-THT + centrifuges

- Non-exclusive marketing, promotion and distribution
- U.S.: general orthopedics, spine and wound care
- Global: Sports Medicine rights under detailed agreement

Existing channel + clinician access

2026 — 2

ORTHOBIOLOGIC EXPANSION

RegenKit® ExtraCell-BMC / RegenBMC

FDA 510(k) cleared May 29, 2026
BK251274/0

- PRP from peripheral blood or a mixture of peripheral blood + bone marrow
- Mixed with autograft / allograft bone before application to a bony defect

Orthopedics + spine adjacency

2027 POTENTIAL — 3

STRATEGIC OPPORTUNITY

Potential extension across all therapeutic indications

2027 broader collaboration opportunity

Existing channel + new orthobiologic clearance

INVESTMENT TAKEAWAY

Existing channel + new orthobiologic clearance create a path to deepen the relationship as RegenLab broadens its U.S. portfolio.

Source: RegenLab USA, Inc. draft Form S-1 Amendment No. 3 (June 16, 2026), prospectus pp. 6, 13 and 94; original management roadshow materials for 2027 objective.

FDA clearance + CMS reimbursement

RegenKit Wound Gel (RegenWound)

FDA 510(k) BK210661 (July 8, 2022), Class II
CE-MDR Class IIb (valid through Dec 31, 2028)
For exudating cutaneous wounds: DFUs, pressure ulcers, and leg ulcers

Cellular Membrane (CellularWound)

Newly EU-MDR certified PRP-HA-Ca combination for advanced wound management

MiMedx – exclusive U.S. distributor as of January 2026

NATIONAL AVG REIMBURSEMENT

In Hospital: $2,107.97
At Home: $1,064.49

per procedure (CY 2024)

CMS REIMBURSEMENT (NCD 270.3)

G0465	Diabetic chronic wounds (DFU)	**$2,107.97**
G0460	Non-diabetic chronic ulcers	**Varies by MAC***

Up to 20 treatments (1/week for 20 weeks), including debridement.
Few PRP competitors hold both FDA clearance and CMS national reimbursement

* MAC = Medicare Administrative Contractor; G0460 reimbursement is not nationally standardized. Reimbursement varies by site of service.

COMMERCIAL PARTNERSHIP

MiMedx | exclusive U.S. distribution + milestone-driven economics

U.S. wound-care channel | non-exclusive launch → exclusive distribution → scale through 2030

JUL 2025 — 1

INITIAL RELATIONSHIP

RegenWound Gel PRP Kit I + Kit II

- Non-exclusive U.S. distribution relationship established
- Commercial collaboration preceded broader exclusivity
- FDA-cleared RegenWound Gel platform

Initial U.S. wound care channel

DEC 2025 — 2

EXCLUSIVE U.S. CHANNEL

Exclusive distributor for RegenWound Gel PRP kits

$5.0M upfront received January 2026

- MiMedx responsible for sales, marketing, training and reporting
- RegenLab supplies products at agreed supply prices
- CMS-reimbursed PRP wound applications

National commercialization platform

THROUGH 2030 — 3

MILESTONE-DRIVEN SCALE

Up to $5.0M additional milestone payments

$1M at each cumulative net sales threshold

$15M • $35M • $65M • $100M • $125M

Agreement through Dec. 31, 2030 + automatic one-year renewals

INVESTMENT TAKEAWAY

Exclusive national distribution + reimbursement + milestone economics create a scalable U.S. wound-care channel with aligned partner incentives

INDUSTRY VALIDATION

Medical society endorsements

Grade A / Level 1 evidence 8 international medical societies · 300+ RegenLab publications

ESSKA

European Society for Sports Traumatology, Knee Surgery & Arthroscopy

AAOS

American Academy of Orthopaedic Surgeons

GRIIP

International Research Group on Platelet Injections

ASPN

American Society of Pain & Neuroscience

SIMTI

Italian Society of Transfusion Medicine & Immunohaematology

ISHA

International Society for Hip Preservation

SIOT

Italian Orthopaedic & Traumatology Society

German WG

German Working Group on Clinical Use of PRP

Field-wide PRP literature (PubMed) is excluded here to avoid conflation with RegenLab-specific evidence.

IP PROTECTION

Global portfolio of 130+ patents

60 patents granted

30 U.S. patents granted

70+ applications pending

PATENTS

PRP + Hyaluronic Acid CellularMatrix Wound	2 granted, 5 pending
Autologous Thrombin Serum Alone/+PRP	10 granted, 3 pending
PRP Alone	10 granted, 2 pending
PRP + Hyaluronic Acid CellularMatrix & RegenMatrix	29 granted, 30 pending
Convalescent Plasma Vaccine-Pasteur	5 pending
PRP+ Cell Culture	5 granted
Liquid Biopsies Cancer Diagnostic	

- Ensures freedom to operate
- Continuous patents listed every year
- INSERM-ICAM France patent on platelet exosomes for liquid biopsies to monitor cancers

MANUFACTURING

Three regional R&D & manufacturing facilities

- Direct access to regulators and market proximity
- Each factory can produce $100M in product sales
- Current worldwide capacity with one shift is $300M in product sales

In anticipation of global market expansion, able to increase from $50 million in sales currently up to $500 million with no capex



New Jersey for
Americas & Australia

Since	**2021**
FTEs	**50**
Sqm	**3,000**
Up to	**2M/yr***

ISO 13485 MDSAP



Paris-Saclay for
Europe

Since	**2024**
FTEs	**40**
Sqm	**3,000**
Up to	**2M/yr***

Certification targeted in Q4 2023



Switzerland for
Middle East & Asia

Since	**2009**
FTEs	**75**
Sqm	**3,000**
Up to	**2M/yr***

ISO 13485 MDSAP EU-MDR 2017/745

LEADERSHIP

Management & board of directors

Antonino Turzi*

Executive Chairman & CEO, Founder

Founded Regen Lab SA in 2003; sole inventor of 100+ patents. Law degree, Paris University.

Jean-Marc Biscarrat

CFO, Director

25+ years financial leadership in US-listed and mid-cap, LBO-backed companies; financial director at Dendrite & KCI.

Dr. Giuseppe Calloni, PhD

CEO, RegenLab USA LLC

25 years in chemical & biotech management; 25 publications, 3 patents. PhD, University of Milan.

Dr. Daphne Metzger, PhD

Chief Operating Officer

Joined Regen Lab in 2010; led ISO 13485 + MDSAP across 3 sites. PhD, University of Geneva.

Carlo Turzi, MBA

Chief Commercial Officer

Joined Regen Lab in 2010; UN University University of Geneva.

Eric Del Cotto

Independent Director

25+ years MedTech management in Europe. President, EffiPerf. Former MD, Owen Mumford.

Chris Fashek**

Independent Director Nominee

30+ years medical device & wound care. Founder & Chairman, MedTech Solutions Group.

Catherine Fuhr**

Independent Director Nominee

25+ years global industrial & manufacturing. Founder, GSI Consulting Group.

Eric Loges**

Independent Director Nominee

Finance & executive leadership. Partner, Seaton Hill Partners. Former CFO, A. Finkl & Sons.

**Antonino Turzi currently has 98.5% voting pre-IPO and will be diluted accordingly post-IPO; RegenLab is a controlled company under NASDAQ rules.*
*** To be appointed immediately prior to effectiveness of registration statement.*

PERIOD OF CONSOLIDATION

2025 financial summary

The France factory opening, the U.S. facilities relocation from Brooklyn to Jersey City, and the modernization of the Swiss factory compressed margins in 2024 and 2025 | 1H 2026 operating income has already reached $2.5 million

($000s)	2025	2024	Change
Net Product Sales	$49,170	$48,382	**+2%**
COGS	$14,934	$13,914	**+7%**
Gross Profit	$34,236	$34,468	**-1%**
Gross Margin	69.6%	71.2%	**-106 bp**
Marketing & Distribution	$15,690	$14,981	**+5%**
G&A	$11,385	$11,774	**-3%**
R&D	$6,486	$4,236	**+53%**
Operating Income	**$675**	**$3,477**	**-81%**

2025 NON-RECURRING ITEMS

U.S. channel realignment
shift to distribution

NJ factory relocation
~$2.4M (reclassified to G&A)

R&D expense increase
+$2.3M (RegenMatrix, BBI)

2025 CASH FLOW

Operating
($542K)

Investing
($1.6M)

Financing
+$3.6M

Net Change
+$888K

2024 figures restated. Income from operations $675K (2025) vs. $3,477K (2024), -81%; net loss $(1,241)K vs. net income $2,312K. R&D rose to $6,486K (13% of revenue). Margin compression driven by France factory launch and U.S. facilities relocation to Jersey City ($2.4M facility cost, reclassified to G&A); gross margin restored to 71.4% in 1Q 2026. The S-1 includes a going-concern qualification.

RESUMED GROWTH

1H 2026 financial performance

($000s)	1H 2026	1H 2025	Change
Net Product Sales	$29,654	$23,378	**+27%**
Gross Profit	$18,747	$14,214	**+32%**
Gross Margin	63.2%	60.8%	**+240 bp**
Total OpEx	($16,289)	($14,732)	**+11%**
Operating Income	**$2,458**	**($518)**	**+$3.0M**
Net Income	$1,050	$770	**+36%**

+27%

YoY growth in net product sales

$4.4M

U.S. net product sales (+67% YoY)

32%

U.S. revenue share (vs 20% in 2025)

$2.5M

Positive operating income

1H 2026 net income $1.1 million, EPS $0.31; positive operating cash flow.

Per S-1 unaudited interim financials; not necessarily indicative of full year.

OUTLOOK

Milestones & growth strategy

2026

U.S. WOUND CARE ACCELERATION

- Wound care: 3% of 2025 revenue → 20% of Q1 2026 revenue (MiMedx)
- IPO proceeds to fund U.S. commercial build-out, CellularMatrix PMA completion

2027

TISSUE ENGINEERING PRODUCT LAUNCH

- CellularMatrix PMA approval late Q1 → U.S. market launch; CPT code ~CYE
- RegenMatrix EU & U.S. launch
- Wound care EU / Asia expansion via distribution partners

2028 - 2029

GLOBAL SCALE

- Full product portfolio deployed globally
- New distribution territories and partnerships
- M&A horizontal growth

IN SUMMARY

Proven commercial base, scalable infrastructure, growth levers

WHAT INVESTORS OWN TODAY

$49.2M	**2025 net product sales**
+27%	**1H26 net product sales growth**
$2.5M	**1H26 operating income**
90+	**Countries served | 2M+ patients treated**

WHAT CAN DRIVE THE NEXT LEG OF GROWTH

1	**U.S. WOUND CARE**	Scale MiMedx-led commercialization and reimbursement-enabled adoption
2	**CELLULARMATRIX U.S.**	Complete PMA pathway and convert approval into launch / market access
3	**PORTFOLIO EXPANSION**	RegenMatrix, orthobiologics, Women's Health and next-generation formats
4	**GLOBAL SCALE**	Broaden partnerships / geographies and pursue horizontal M&A

INVESTMENT TAKEAWAY

Established global regenerative-medicine business + proprietary platform + catalyst-rich U.S. growth plan

Sources: Company materials; draft Form S-1, Amendment No. 3 (June 16, 2026).

INVESTOR RELATIONS

RegenLab USA, Inc.

CORE IR

bruce@coreir.com

regenlab.com

Proposed Nasdaq: RGNA



A global leader in regenerative medicine for orthopedics, wound care, dermatology, and women's health

APPENDIX

regenlab
PRP & CELL THERAPY SPECIALISTS

APPENDIX


One core technology, multiple regenerative applications

Closed-system PRP preparation supports a modular portfolio of autologous biologic formats.

1 PATIENT-DERIVED INPUT

PATIENT'S OWN BLOOD

2 STANDARDIZED PREPARATION



Preset collection • single centrifugation • closed circuit

3 MODULAR PRODUCT FORMATS

1. Liquid PRP
2. PRP + HA
3. Gel / Fibrin
4. BMC + PRP

Same biological foundation, tailored for different procedures and indications

THERAPEUTIC APPLICATIONS

01 **Musculoskeletal**
Joint, tendon & bone

02 **Advanced Wound Care**
Chronic & surgical wounds

03 **Medical Aesthetics**
Skin & dermatology

04 **Women's Health**
Urogynecology

INVESTOR TAKEAWAY

A standardized PRP preparation platform provides a common foundation for multiple product configurations and therapeutic markets.

Source: RegenLab USA, Inc. Form S-1, Amendment No. 3 (June 16, 2026).

APPENDIX

PRP + HA platform: two complementary formulations

Same autologous PRP foundation; HA formulation and target disease stage differentiate the products.

CELLULARMATRIX®

COMMERCIAL / CE-MDR

PRP + linear hyaluronic acid

Primary positioning

Moderate knee osteoarthritis (KL Grade III)

U.S. regulatory status

Modular PMA in process

Product concept

Linear HA is positioned for shorter intra-articular residence and rapid symptom support.



REGENMATRIX®

PIPELINE

PRP + crosslinked hyaluronic acid

Primary positioning


Advanced knee osteoarthritis (KL Grade IV)

U.S. regulatory status

PMA pathway expected; no U.S. authorization currently

Product concept

Crosslinked HA is designed for longer residence time and added biomechanical support.



Complementary by disease severity and product characteristics — positioned as distinct offerings rather than direct substitutes.

Source: RegenLab USA, Inc. Form S-1, Amendment No. 3 (June 16, 2026).

Strong scientific and educational platform | Biobridge Foundation

- Based on **20 years of experience**, **these 6 books** are intended for physicians who practice and conduct research in disciplines where PRP represents a therapeutic option.
- Biobridge Congress and Conference, Biobridge Workshops and Webinars



APPENDIX

U.S. regulatory roadmap across four platforms

Portfolio spans FDA-cleared products, active PMA/IDE programs and pre-submission development.

MUSCULOSKELETAL

RegenKit PRP
CLEARED

FDA 510(k) cleared

RegenBMC
CLEARED

FDA 510(k) cleared May 2026

CellularMatrix
ACTIVE

Modular PMA in process

RegenMatrix
PIPELINE

PMA pathway expected; no U.S. authorization

ADVANCED WOUND CARE

RegenWound
CLEARED

FDA 510(k) cleared; CMS-reimbursed

CellularWound
PRE-SUBMISSION

510(k) submission in preparation

RegenKit Surgery
CLEARED

FDA cleared under RegenKit THT

MEDICAL AESTHETICS

CellularMatrix Skin
IDE / CLINICAL

IDE clinical evaluation; not cleared/approved

RegenKit PRP
PRE-SUBMISSION

De Novo submission in preparation

SkinVisc
PRE-SUBMISSION

PMA submission in preparation

WOMEN'S HEALTH

CellularMatrix Skin
PLANNED

PMA pathway anticipated; no action yet

SkinVisc
PLANNED

PMA pathway anticipated; no action yet

RegenKit PRP
PLANNED

De Novo pathway anticipated; no action yet

STATUS KEY — CLEARED | ACTIVE / CLINICAL | PRE-SUBMISSION / PLANNED


Regulatory status summarized from the June 16, 2026 S-1; timing and outcomes remain subject to regulatory review.

Source: RegenLab USA, Inc. Form S-1, Amendment No. 3 (June 16, 2026).

APPENDIX

Strong clinical evidence demonstrated by Cellular Matrix®


Multicentric study comparing CellularMatrix to ArthroVisc and Ostenil Plus[1]



53 patients (40-80 years) with knee OA (90 knees tested)

CellularMatrix, under a 3-injection regimen, delivered a high statistically significant improvement (p< 0.01) at 6 month of 71.1% vs. 28.9% for ArthroVisc and 33.5% for Ostenil Plus, in the Total WOMAC inverted, also after 12 months

Multicentric, prospective, randomized controlled trial comparing CellularMatrix to Synvisc-One®[2]



156 patients (40-80 years) with symptomatic femorotibial KOA

CellularMatrix, under a single injection regimen, delivered a statistically significant improvement at 6 month of 35,2% vs. 16,6% for comparator, in the WOMAC1 sub-score related **to pain on walking** after one single injection p= 0.044

1. Barac, B., et al. (The new treatment approach in knee osteoarthritis: Efficacy of CellularMatrix combination of platelet-rich plasma with hyaluronic acid versus two different types of hyaluronic acid (HA). Int. J. Clin. Rheumatol. 2018;13(5):289-9
2. T. Delagado et al, 2022, vol 89, Revue du Rhumatisme

APPENDIX

RegenLab has invented PRP & cell therapies in skincare, a fast-growing market

2.6 million dermo-aesthetics procedures per year in the U.S. using HA-including products[1]

Other PRP markets

CellularMatrix

RegenKit PRP skincare



Indications: Skin Texture, Scar, Post-Laser, Facelift, Alopecia, Wrinkle Filling, Cellulitis, Ptosis

+

Cellular Matrix skincare

Regen4D®

Unique range of products to boost the skin's natural regeneration process



Bring value to Regen Lab patients throughout their skincare journey

Dermo-aesthetics product lines and brand capitalizing on Regen Lab medical expertise in PRP and HA

The Skincare market represents ~45% of Regen Lab sales in 2022


Multiple lateral applications now and in development (e.g. urogenital, alopecia)

Proprietary best-in-class PRP technologies, alone or combined with hyaluronic acid

25 years ago, pioneering PRP, Regen Lab has become the frontrunner in autologous tissue engineering


RegenKit

Standardized autologous PRP THERAPY PROCESS for healthy tissue



CellularMatrix


Tissue engineering INNOVATION (PRP & HA) for complex tissue



Hyaluronic Acid

What is PRP practically?





APPENDIX

One PRP technology | four product formats

Four standardized product inputs support multiple regenerative applications across RegenLab's therapeutic platforms.

FOUR PRP-BASED PRODUCT FORMATS

01 LIQUID PRP

Injectable PRP solution

02 PRP + HA

Combination with hyaluronic acid

03 PRP GEL / FIBRIN MATRIX

Activated PRP for gels, membranes and bio-glue

04 PRP + CELLS (BMC)

PRP combined with bone marrow concentrate / cellular components

Common biological foundation / shared infrastructure → format tailored to clinical workflow and indication

THERAPEUTIC APPLICATIONS

MUSCULOSKELETAL

Joint, tendon & bone

- Liquid PRP
- PRP + HA
- PRP + Cells (BMC)
- Fibrin Matrix

ADVANCED WOUND CARE

Chronic & surgical wounds

- PRP Gel / Fibrin Matrix
- Liquid PRP
- PRP + HA
- PRP + Cells (BMC)

MEDICAL AESTHETICS

Skin & dermatology

- Liquid PRP
- PRP + HA
- PRP Gel / Fibrin Matrix
- PRP-derived supplements

WOMEN'S HEALTH

Urogynecology

- Liquid PRP
- PRP + HA
- PRP Gel / Fibrin Matrix
- PRP + Cells (BMC)


Source: Company materials; draft Form S-1, Amendment No. 3 (June 16, 2026).

APPENDIX

PRP standardization | Thixotropic gel separation

Polymer gel viscosity is the key technology: density-based separation isolates plasma / platelets from denser blood-cell components.


POST-CENTRIFUGATION PROFILE



HOW THE THIXOTROPIC GEL WORKS

1. **SOLID AT REST**
   Stable polymer barrier before centrifugation
2. **FLUID UNDER FORCE**
   Becomes fluid at ~1,500 g during centrifugation
3. **MIGRATES BY DENSITY**
   Moves between desired PRP fraction and denser blood cells
4. **REFORMS BARRIER**
   Returns to solid consistency after centrifugation

BLOOD COMPONENT DENSITY



STANDARDIZATION OUTCOMES

>99.7%
RBC elimination

80–95%
typical platelet recovery

5 or 9 min
centrifugation

Source: draft Form S-1, Amendment No. 3, “RegenKit and Regen Tubes” / PRP preparation technology.

APPENDIX

Broad commercial portfolio

Platform	Product (partial list)	Description	EU Status	U.S. Status
Osteoarthritis Musculoskeletal	**Arthrovisc**	Linear HA	CE-marked & marketed	FDA application soon
	RegenKit	PRP only	CE-marked & marketed	510(k)-cleared & marketed
	CellularMatrix	PRP + linear HA	CE-marked & marketed	Modular PMA in process
	RegenMatrix	PRP + crosslinked HA	Last pivotal study completed	Breakthrough designation in progress
DFU Wound Care	**RegenWound**	PRP-based gel	CE-marked & marketed	510(k)-cleared & marketed
	CellularWound	PRP-HA membrane gel	CE-marked	510(k) submitted and under review
Medical Aesthetics	**CellularMatrix Skin**	PRP + linear HA	CE-marked & marketed	--
	RegenKit	PRP only		
Women's Health	**CellularMatrix Skin**	PRP + linear HA	--	--
	SkinVisc	HA syringe		PMA submission is in preparation

90+
countries served

32
Staff regulatory

2M+
patients treated

300+
clinical publications

BSI-certified since 2019 (all sites) | **USA · Canada · Australia · Brazil · Japan** | **Full certification across product line**